OBJECTIVE： To systematically evaluate therapeutic efficacy of Xuefu zhuyu decoction in the adjuvant treatment of unstable angina pectoris （UAP）， and to provide systematic evidence-based reference in clinic. METHODS： Retrieved from PubMed， EMBase， Cochrane library， CJFD， Wanfang database， VIP and CBM， randomized controlled trials （RCTs） about Xuefu zhuyu decoction+conventional treatment （trial group） vs. single conventional treatment （control group） in the treatment of UAP were collected.  Meta-analysis was performed by using Rev Man 5.2 statistical software after data extraction and Cochrane systematic review manual 5.1.0. RESULTS： Totally 12 RCTs were included， involving 1 252 patients. The results of Meta-analysis showed that total response rate [OR＝3.56，95％CI（2.49，5.10），P＜0.001]， serum HDL[WMD＝0.25，95％CI（0.05，0.45），P＝0.01] and the rate of ECG improvement [OR＝2.76，95％CI（1.97，3.87），P＜0.001] of trial group were significantly higher than those of control group， while serum TC [WMD＝－1.14，95％CI（－1.46，－0.82），P＜0.001]， TG [WMD＝－0.53，95％CI（－0.84，－0.22），P＜0.001] and CRP [WMD＝－0.91，95％CI（－1.14，－0.69），P＜0.001] levels of trial group were significantly lower than those of control group， with statistical significance. CONCLUSIONS： Therapeutic efficacy of Xuefu zhuyu decoction in adjuvant treatment have good therapeutic efficacy and can significantly improve the blood lipid and inflammatory factors level.